Close Menu

GSK

This story originally ran on Dec. 13.
Biodesix last week presented results from a retrospective analysis of breast cancer patients using its serum proteomic Veristrat diagnostic.

Proteomics firm Cellzome said this week it has won more than €2.3 million ($3.1 million) in grants funding its participation in three separate research projects.

Abbott said this week that it has expanded an existing immunotherapy companion diagnostic development agreement with GlaxoSmithKline to include a new target antigen.

Originally published Nov. 29.
Abbott and GlaxoSmithKline this week formally extended an existing drug/diagnostic codevelopment partnership in the cancer immunotherapy space, setting their sights on a new marker: the PRAME antigen.

By Doug Macron
Alnylam Pharmaceuticals this week unveiled an initiative to apply its RNAi technology to the production of vaccines and announced that GlaxoSmithKline will be its first partner for the platform.

By Ben Butkus
This story has been updated from a version posted Oct. 25 to include comments from a GlaxoSmithKline spokesperson.

Pages

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.